Teijin Pharma and SCYNEXIS Sign Research Agreement
Scynexis
Teijin Pharma and SCYNEXIS Sign Research Agreement
RESEARCH TRIANGLE PARK, North Carolina, October 13/PRNewswire/ --
SCYNEXIS, Inc., a medicinal chemistry-focused drug discovery and development company,
today announced that Teijin Pharma Limited, an R&D-oriented pharmaceutical company
which is a wholly owned subsidiary of Teijin Limited, and SCYNEXIS have signed an
agreement under which SCYNEXIS will provide comprehensive medicinal and analytical
chemistry services to Teijin Pharma's research programs. The financial terms of the
agreement were not disclosed.
The agreement provides Teijin Pharma with dedicated chemistry resources including a
highly experienced SCYNEXIS medicinal chemistry team backed by proprietary, innovative
technologies.
'SCYNEXIS is pleased to work with Teijin Pharma in its novel drug discovery and
development efforts and to have Teijin Pharma as one of SCYNEXIS' valued customers in the
important Japanese market,' said Yves Ribeill, President and Chief Executive Officer of
SCYNEXIS. 'SCYNEXIS has now firmly established relationships in Japan, Europe and the
U.S. confirming its ability to deliver valuable capabilities and technologies to a wide
range of customers.'
About Teijin Pharma Limited
Teijin Pharma Limited (www.teijin-pharma.co.jp/) was established in October
2003 as the result of the spin-off of the Pharmaceutical Business Unit and the Home
Healthcare Business Unit from Teijin Limited. Teijin Pharma offers total healthcare in
three focus areas -- respiratory disease, bone and joint disease, and cardiovascular and
metabolic disease -- by providing advanced medical services in the fields of
pharmaceuticals and home healthcare.
Teijin Limited (www.teijin.co.jp/), established in 1918, is a 100% shareholder
of Teijin Pharma and is the holding company of Teijin Group which is active in a wide
range of businesses, including fibers, films, plastics, pharmaceuticals and home health
care, and information technology (IT)-related services.
About SCYNEXIS
SCYNEXIS is a medicinal chemistry-focused drug discovery and development company
headquartered in Research Triangle Park, North Carolina. By combining its chemists'
extensive expertise with its proprietary, cutting-edge technologies MEDCHEM-FACTORY(TM),
HEOS(R) Software Suite and Kinase Inhibitor Technology (KIT(TM)), SCYNEXIS provides
improved speed and productivity in the chemical validation of drug targets. Besides
SCYNEXIS' validated expertise in lead optimization and candidate selection, SCYNEXIS also
offers a comprehensive suite of drug discovery and development services that include novel
directed hit generation compounds, hit explosion and lead optimization services, process
optimization, purification and analysis of compound libraries, bioanalytical services and
the production of GMP clinical samples. SCYNEXIS' website is located at
www.scynexis.com.
Web site: www.scynexis.com
www.teijin.co.jp
www.teijin-pharma.co.jp
Source: SCYNEXIS, Inc.
SCYNEXIS Media Contact, Rick Rountree of Rick Rountree Communications, +1-919-878-1144, or
Rick@Rickrountree.com; or SCYNEXIS Market Development Contact, Terry Marquardt of
SCYNEXIS, Inc., +1-919-544-8600, or Terry.marquardt@scynexis.com